Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0T8LY
|
||||
| Former ID |
DNC004080
|
||||
| Drug Name |
PYRIDINE
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Phase 4 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C5H5N
|
||||
| Canonical SMILES |
CN1CCCC1C2=CN=CC=C2.C(C(C(=O)O)O)(C(=O)O)O
|
||||
| InChI |
1S/C10H14N2.C4H6O6/c1-12-7-3-5-10(12)9-4-2-6-11-8-9;5-1(3(7)8)2(6)4(9)10/h2,4,6,8,10H,3,5,7H2,1H3;1-2,5-6H,(H,7,8)(H,9,10)
|
||||
| InChIKey |
QLDPCHZQQIASHX-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Thromboxane-A synthase | Target Info | Inhibitor | [2] | |
| BioCyc Pathway | C20 prostanoid biosynthesis | ||||
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| Platelet activation | |||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | ||||
| Arachidonic acid metabolism | |||||
| Phase 1 - Functionalization of compounds | |||||
| Eicosanoid Synthesis | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02143167) Resistance Training and Amino Pyridine in Multiple Sclerosis. U.S. National Institutes of Health. | ||||
| REF 2 | J Med Chem. 1981 Oct;24(10):1149-55.Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.